XML 33 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Collaborations and Other Arrangements (Tables)
 9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of significant milestones and revenue recognized
The table below summarizes the net amount of significant milestones capitalized (deferred) at September 30, 2021 and December 31, 2020 for the compounds included in this collaboration:
Net Milestones Capitalized (Deferred) (1) as of:
Product FamilySeptember 30, 2021December 31, 2020
Jardiance (2)
$141.1 $156.2 
Trajenta (3)
95.1 114.6 
Basaglar(154.0)(168.0)
(1) In connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. In connection with the regulatory approvals of Basaglar, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. This represents the amounts that have been capitalized (deferred) from the start of this collaboration through the end of the reporting period, net of amount amortized.
(2) The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
(3) The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto.
The following table summarizes our collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products and our net product revenue recognized with respect to Basaglar:
Three Months Ended September 30,Nine Months Ended September 30,
Product Family2021202020212020
Jardiance$390.4 $310.8 $1,058.9 $840.3 
Basaglar192.8 248.2 650.1 842.3 
Trajenta96.1 91.7 279.9 261.7 
The following table summarizes our net product revenue recognized with respect to Olumiant:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Olumiant$406.9 $162.0 $809.1 $446.7 
The following table summarizes our revenue recognized in China with respect to Tyvyt:
Three Months Ended September 30,Nine Months Ended September 30,
2021202020212020
Tyvyt$125.6 $84.4 $340.2 $205.9